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A B S T R A C T
We present a 70-year-old man from Dalmatia, Croatia, with a history of prolonged high fever diagnosed as Q fever
endocarditis. As far as we know, this is the first case of chronic Q fever in Croatia. The treatment was started as for cul-
ture-negative endocarditis, but was without clinical response. After significantly high anti-phase I IgG plus IgA antibod-
ies titers to Coxiella burnetii were shown, the initial treatment with doxycycline was changed and ciprofloxacin was
started with good clinical response.
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Introduction
Q fever has been a well-known and mandatory nota-
ble disease in Croatia from 19541. It usually occurs spo-
radically as an occupational disease in areas predomi-
nantly rich with sheep and goats. The first greater out-
breaks in Dalmatia have been reported quite recently2.
Typically, in Croatia the disease manifests as atypical
pneumonia. Until the present no Q fever endocarditis
has been described.
Case Report
A 70-year-old sheep farmer from North Dalmatia was
admitted to Zadar General Hospital due to prolonged
two-week high intermittent fever and minimal paroxys-
mal coughing, not previously treated with antibiotics.
His past medical history was significant only for paroxys-
mal atrial fibrillation and mitral valve prolapse eviden-
ced two years earlier. On examination, he had an ejection
holostistolic murmur that radiated to the axillar region,
and 3-centimeter splenomegaly. Routine blood tests re-
vealed ESR 85 mm/h, CRP 37 mg/L, Hemoglobin 12.6
g/dL; white-cell count 10.5x109/L with 76% neutrophiles,
10% lymphocytes, 7% monocytes, 4% band forms; pla-
teets 253,000/mm3; aspartate aminotransferase 29 U/L,
alanine aminotransferase 24 U/L; blood glucose 6.4
mmol/L urea nitrogen 4.2 mmol/L, creatinine 73 mmol/L;
total protein 82.0 g/L (gamma globulins 34.2%). Due to
the fact that splenomegaly suggested the possibility of
malignancy, chest X-ray, abdominal ultrasound, urologic
examination, bone marrow aspiration, gastroscopy and
tumor markers were performed, and all were normal.
Transthoracic (TTE) and transoesophageal echocardio-
gram (TEE) revealed mitral valve prolapse with moder-
ate mitral regurgitation; but without visible vegetations.
Serial blood cultures (anaerobic and aerobic), as well
as the bone marrow culture for the isolation of Brucella
spp., were negative. The patient was initially treated
with ampicilin and gentamicin+ceftriaxon with no clini-
cal response. After the pair serological testing for Coxie-
lla burnetii antibodies proved positive, (ELISA tests for
Bartonella spp., Legionella spp. and Chlamydia spp. were
negative as well as the serum agglutination and comple-
ment fixation tests for Brucella spp.), a combination of
doxycycline and ciprofloxacin was started. Several days
after the patient became afebrile; he was discharged and
sent home to be followed-up clinically and serologically
as an outpatient (Table 1).
Three months later, ciprofloxacin was replaced by
hydroxychloroquine with further good clinical result and
no adverse effects. Therefore, the patient was told to con-
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tinue with the treatment for another 12 months, 18
months in total. Repeated transthoracic echocardiogram
showed no new changes in this period. Also, routine
blood tests became normal and splenomegaly resolved.
Discussion
In Croatia, Q fever has been known almost exclu-
sively through the clinical feature of atypical pneumo-
nia3–5. Since Dalmatia is an old endemic Q fever area, for
years all culture-negative endocarditis have been sear-
ched for Coxiella burnetii antibodies but without further
systematical follow-up of the patients after the acute Q
fever phase. To our knowledge, this case represents the
first documented Q fever endocarditis in Croatia.
In some countries it is estimated that Q fever endo-
carditis represents 8.7–11% of all reported Q fever cases;
in France it represents 5% of endocarditis cases with the
incidence of 1 case per million inhabitants per year6,7.
Also, it is estimated that the risk of transformation from
acute Q fever to endocarditis is about 40% in patients
with valvulopathy8. In our patient acute Q-fever mani-
fested as a flu-like illness transformed into chronic dis-
ease very soon, after a few weeks. It is possible that rela-
tively quick disappearance of phase I antibodies to C.
burnetii is the result of prompt and appropriate treat-
ment given after positive serology was obtained. In many
cases the development of endocarditis after acute Q fever
may take months to years9,10.
Endocarditis with a negative blood culture accounts
for up to 48% of infective endocarditis cases11–14. About
half of the cases is due to previous antibiotic treat-
ment13,15 while the main other causes are fastidious
growing bacteria. In the case of our patient, who had not
been previously treated with antibiotics, blood and bone
marrow cultures were negative as were the other se-
rological tests except that for C. burnetii. Among the fas-
tidious microorganisms, the most common identified are
Coxiella burnetii and Bartonella spp., rarely Brucella
spp., Abiotrophia spp., HACEK group, Listeria monocy-
togenes and very rarely Legionella spp., Mycoplasma
spp., Aspergillus spp. etc.6,7,16. Routine serological test-
ing for these bacteria depends on the local epidemiologi-
cal feature and local standards. In this regard, broad-
-range PCR and sequencing could be helpful for identifi-
cation of bacterial DNA17,18.
The diagnosis of Q fever endocarditis by echocar-
diography is problematic because the vegetations are ab-
sent or small. In this regard, TEE appears to be of
greater usefulness than TTE because of better sensitiv-
ity and possibility for detecting mechanical complica-
tions19,20. The usefulness of echocardiography has led to
its inclusion in the so-called »Duke-criteria« for the diag-
nosis of endocarditis. This criterion classifies the diagno-
sis of infective endocarditis and then echocardiographic
findings21. Moreover, some reports suggested that modi-
fication of current diagnostic criteria was required and
that would include serology and molecular diagnostic of
fastidious bacteria22–24. It is estimated that the overall
sensitivity of the Duke criteria is about 80%. By using se-
rologic methods for identification of fastidious microor-
ganisms about 9% of IE patients with negative blood cul-
ture could be reclassified from »definite IE« category to
»possible IE« and about 7% from »rejected IE« to »possi-
ble IE«16. The molecular PCR method has led to an in-
crease in sensitivity of the Duke criteria, but, at the same
time, to a decrease in specificity; moreover, at present
there is no standardization of this methodology.
In the case of Coxiella burnetii endocarditis,the most
commonly used serologic methods are indirect immuno-
fluorescence assay (IFA) and enzyme-linked immuno-
sorbent assay (ELISA)25,26. IFA test is needed as confir-
matory test only in the case of negative EIA (enzyme
immunoassay) test26. Antibodies to phase I and phase II
can be determined in the IgG, IgM and IgA classes. Q fe-
ver endocarditis is characterized by a very high titer of
anti-phase I IgG antibodies.
The treatment of Q fever endocarditis evolved through
the years, and, at present, the optimal regimen include
doxycycline in combination with fluoroquinolone or with
hydroxychloroquine27–29. The first combination should
last at least 3 years, the second at least 18 months. Q fe-
ver is considered cured when the anti-phase IgG titers
are less than 80030.
Conclusion
Q fever endocarditis occurs principally in patients
with valvular damage and is diagnosed according to the
modified Duke criteria7,8. Some authors proposed that
every patient with acute Q fever and valvulopathy should
be followed-up serologically for at least 2 years, if neces-
sary by PCR and also by TTE8,31,32. This approach could
be of great help because in patients with valvular damage
there exists the significant risk of endocarditis, and spe-
cially because endocarditis could happen many years af-
ter acute infection10,33. Moreover, some authors suggest
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*ELISA – enzyme-linked immunosorbent assay
1borderline index 0.9–1.1; 2positive index >1.1; 3negative index
that all the patients with acute Q fever, irrespective
whether the underlying factors exist or not, should be
systematically tested for anti-phase I and II Coxiella
burnetii antibodies at 3 to 6 months intervals after the
disease onset34. Our case report supports these recom-
mendations which can be very useful in Q fever endemic
areas like Dalmatia in Croatia.
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PRVI SLU^AJ KRONI^NE Q GROZNICE S ENDOKARDITISOM I KRATKI PREGLED
S A @ E T A K
Prikazujemo slu~aj 70-godi{njeg bolesnika iz Dalmacije kod kojega je nakon dugotrajne vru}ice dokazan endokar-
ditis kao kroni~ni oblik Q groznice. Prema na{im saznanjima radi se o prvom takvom slu~aju u Hrvatskoj. Lije~enje je
zapo~eto kao u kultura-negativnih endokarditisa bez klini~kog odgovora. Nakon dobivanja nalaza visokih titrova IgG i
IgA protutijela na fazu I Coxielle burnetii terapija je promjenjena u doksiciklin i ciprofloksacin s dobrim klini~kim
odgovorom.
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